Emerging Infections Network Survey of Screening for Cryptococcal Antigenemia, United States, 2024
We polled infectious disease specialists about cryptococcal antigen screening for patients initiating HIV antiretroviral therapy. Of 215 respondents, 33% reported typically obtaining screening for patients with CD4 counts <200 cells/mm<sup>3</sup> and 63% for counts <100 CD4 cells/mm<sup>3</sup>. Uncertainty about cryptococcal antigen screening benefits and recommendations suggests opportunities for education and increased screening.
Authors
- Ian Hennessee (ORCID: https://orcid.org/0000-0001-8807-9566)
- Tom Chiller
- Susan E. Beekmann (ORCID: https://orcid.org/0000-0003-0278-506X)
- Philip M. Polgreen (ORCID: https://orcid.org/0000-0002-0630-5898)
- Dallas J. Smith (ORCID: https://orcid.org/0000-0001-5707-528X)
- Alexander Jordan (ORCID: https://orcid.org/0000-0002-7834-866X)
- Kaitlin Benedict (ORCID: https://orcid.org/0000-0003-0458-2493)
- Jeremy A.W. Gold (ORCID: https://orcid.org/0000-0002-5054-7616)
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2025-06-24
- DOI
- https://doi.org/10.3201/eid3107.250295
- Citations
- 1
- Primary Topic
- Fungal Infections and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35